Status: Not yet recruiting
A Study of KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple Myeloma
A single-arm, open-label, multicenter, dose-escalation clinical trial to evaluate the safety, tolerability, and preliminary efficacy of KIV-318 Injection in patients with relapsed/refractory multiple myeloma.
Participants needed: 30
Trial details
Phase: Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: Institute of Hematology & Blood Diseases Hospital, ChinaUpdated: Jul 24, 2026Locations: 1
Eligibility criteria
Age between 18 and 70 years (inclusive), regardless of gender; [+5]
Receipt of any type of T-cell engager (TCE) therapy within 8 weeks or 5 half-liv... [+12]